Lv51
1560 积分 2021-06-21 加入
Targeting Cancer: A New Era in Cancer Therapy through Immune Fitness Modulation and KRAS Degradation
4天前
已完结
Innovative Cancer Therapies: Targeting Oncogenic Pathways through Placental Immunology, PROTAC Technology, and Kinase Degradation
4天前
已完结
Discovery of highly potent and selective KRASG12C degraders by VHL-recruiting PROTACs for the treatment of tumors with KRASG12C-Mutation
6天前
已完结
Efficient targeted oncogenic KRASG12C degradation via first reversible-covalent PROTAC
6天前
已完结
Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
6天前
已完结
A CuMoO4 nanocatalyst for Csp2–O cross-couplings; easy access to nitrofen derivatives
1个月前
已完结
A CuMoO4 nanocatalyst for Csp2–O cross-couplings; easy access to nitrofen derivatives
1个月前
已完结
KRAS mutation: from undruggable to druggable in cancer
1个月前
已完结
Identification of a novel potent CDK inhibitor degrading cyclinK with a superb activity to reverse trastuzumab-resistance in HER2-positive breast cancer in vivo
1个月前
已完结
Discovery of 3-(3-(4-(1-Aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (ARQ 092): An Orally Bioavailable, Selective, and Potent Allosteric AKT Inhibitor
1个月前
已完结
皖公网安备34019202002308
